The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we manage metabolic disorders. These innovative therapies belong to a class known as GLP-1 receptor agonists, which mimic the effects of a natural hormone that manages blood sugar levels and hunger. Originally, developed for diabetes, their effectiveness